SAN DIEGO, Jan. 4, 2022 /PRNewswire/ -- Regulus
Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company
focused on the discovery and development of innovative medicines
targeting microRNAs (the "Company" or "Regulus"), today announced
that Jay Hagan, President and Chief
Executive Officer of Regulus, will present at the H.C. Wainwright
Virtual BioConnect Conference being held from January 10-13, 2022. An on-demand webcast
presentation will be available on Monday, January 10,
2022 at 7:00 a.m. ET.
A webcast of the presentation will be available under "Events
and Presentations" through the investor relations section of the
Company's website at www.regulusrx.com. A replay of the webcast
will be archived for 30 days following the presentation date.
About Regulus
Regulus Therapeutics Inc. (Nasdaq: RGLS) is a
biopharmaceutical company focused on the discovery and development
of innovative medicines targeting microRNAs. Regulus has
leveraged its oligonucleotide drug discovery and development
expertise to develop a pipeline complemented by a rich intellectual
property estate in the microRNA field. Regulus maintains its
corporate headquarters in San Diego, CA.
Forward-Looking Statements
Statements contained in this presentation regarding matters that
are not historical facts are "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995, including statements associated with the Company's employees
and their potential impact on our research and development
programs. Because such statements are subject to risks and
uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Words such
as "believes," "anticipates," "plans," "expects," "intends,"
"will," "goal," "potential" and similar expressions are intended to
identify forward-looking statements. These forward-looking
statements are based upon Regulus' current expectations and involve
assumptions that may never materialize or may prove to be
incorrect. Actual results and the timing of events could differ
materially from those anticipated in such forward-looking
statements as a result of various risks and uncertainties, which
include, without limitation, risks associated with the process of
discovering, developing and commercializing drugs that are safe and
effective for use as human therapeutics and in the endeavor of
building a business around such drugs, and the risk additional
toxicology data may be negative. In addition, while Regulus expects
the COVID-19 pandemic to adversely affect its business operations
and financial results, the extent of the impact on Regulus' ability
to achieve its preclinical and clinical development objectives and
the value of and market for its common stock, will depend on future
developments that are highly uncertain and cannot be predicted with
confidence at this time, such as the ultimate duration of the
pandemic, travel restrictions, quarantines, social distancing and
business closure requirements in the U.S. and in other
countries, and the effectiveness of actions taken globally to
contain and treat the disease. These and other risks are described
in additional detail in Regulus' filings with the Securities
and Exchange Commission, including under the "Risk Factors" heading
of Regulus most recently quarterly report on Form 10-Q.
All forward-looking statements contained in this press release
speak only as of the date on which they were made. Regulus
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/regulus-therapeutics-to-present-at-the-hc-wainwright-virtual-bioconnect-conference-301450012.html
SOURCE Regulus Therapeutics Inc.